SynthesisBMC cancer2025
Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlthough durvalumab or pembrolizumab combined with gemcitabine plus cisplatin (GC) remains the standard first-line therapy, novel targeted agents and immunotherapies integrated with chemotherapy have demonstrated promising efficacy. However, the crosswise comparison between each regimen is rare. Therefore, we comparative the efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer.
methodsWe included 18 randomized controlled trials (RCTs) meeting selection criteria to evaluate first-line targeted/immunotherapy-chemotherapy combinations for advanced BTC. Among them, 15 RCTs were analyzed via Bayesian network meta-analysis (NMA) for the average group, while 6 RCTs were used for pairwise meta-analyses of molecular subgroups, with three studies contributing to both analyses. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and serious adverse events (SAEs). Subgroup analyses were performed for KRAS wild-type and PD-L1-positive populations.
resultsDurvalumab (HR 0.76, 95% CI 0.64-0.91) and pembrolizumab (HR 0.83, 95% CI 0.72-0.95) combined with GC significantly improved OS versus chemotherapy alone, with comparable SAE rates. Sintilimab plus anlotinib and GC achieved the best PFS (HR 0.47, 95% CI 0.28-0.80), though OS benefits were nonsignificant. EGFR inhibitors prolonged PFS in KRAS wild-type patients (HR 0.72, 95% CI 0.52-0.98). Bintrafusp alfa and cetuximab showed higher SAE risks (OR 2.26 and 1.95, respectively).
conclusionOur findings directly inform clinical guidelines, address gaps in current therapeutic decision-making. Durvalumab or pembrolizumab combined with GC are optimal first-line regimens for advanced BTC, balancing survival benefits and safety. Sintilimab plus anlotinib combined with GC demonstrates superior PFS but requires further validation. While EGFR inhibitors plus chemotherapy demonstrate potential in KRAS wild-type patients, confirmation in large-scale RCTs is required. PD-L1 expression may represent a promising predictive biomarker for response to PD-1 inhibitor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.